Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Winston Webster

Urology Dallas, TX Medical Doctor

NPI 1336128214 CMS profile 242260

3417 Gaston Ave, Suite 830, Dallas, TX 75246

Open in the dashboard

General payments

$22,584

431 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Winston Webster of Dallas, TX is reported in the CMS Open Payments database as having received $22,584 across 431 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,834 75
2024 General $1,846 74
2023 General $1,516 76
2022 General $4,996 72
2021 General $597 35
2020 General $938 20
2019 General $10,857 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Winston Webster
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Winston Webster were reported at $1,834. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Winston Webster Urology median Middle half National median
2019 $10,857 $480 $147–$1,201 $163
2020 $938 $246 $87–$645 $114
2021 $597 $358 $111–$1,000 $132
2022 $4,996 $476 $143–$1,263 $149
2023 $1,516 $560 $168–$1,461 $160
2024 $1,846 $563 $170–$1,464 $164
2025 $1,834 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $14,754 100 payments
  2. Janssen Biotech, Inc. $713 31 payments
  3. AstraZeneca Pharmaceuticals LP $600 6 payments
  4. Dendreon Pharmaceuticals LLC $554 28 payments
  5. Sumitomo Pharma America, Inc. $550 26 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $415 20 payments
  7. Pfizer Inc. $324 16 payments
  8. AbbVie, Inc. $274 12 payments
  9. Blue Earth Diagnostics Limited $249 13 payments
  10. Lexington Medical, Inc. $234 1 payment
  11. Other $3,915 178 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,855 5 payments
  2. Food and Beverage $9,160 415 payments
  3. Education $569 11 payments
Products named General payments · program years 2019–2025
  1. MYRBETRIQ $13,576 48 payments
  2. XTANDI $1,177 68 payments
  3. ERLEADA $707 31 payments
  4. LYNPARZA $600 6 payments
  5. PROVENGE $554 28 payments
  6. Xofigo $378 18 payments
  7. ORGOVYX $351 14 payments
  8. GEMTESA $343 20 payments
  9. Nubeqa $293 14 payments
  10. XIAFLEX $273 14 payments
  11. Other $5,010 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,066

Median for Urology: 1,053

Drug cost

$2,540,881

Median for Urology: $101,464

Branded share of claims

34.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 141 $1,933,409
Orgovyx Relugolix Brand 151 $398,142
Myrbetriq Mirabegron Brand 147 $92,651
Gemtesa Vibegron Brand 99 $84,684
Tamsulosin Hcl Generic 622 $8,254
Finasteride Generic 294 $3,703
Solifenacin Succinate Generic 42 $3,444
Potassium Citrate Er Potassium Citrate Brand 32 $2,977
Estradiol Generic 30 $1,942
Silodosin Generic 16 $1,670

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 113 billing codes

Paid by Medicare

$464,153

Of which drugs: $159,021

Medicare patients

822

Average age 74

Services billed

8,093

156 women, 666 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 44%
Arthritis 41%
Chronic kidney disease 34%
Ischemic heart disease 31%
Diabetes 29%
Atrial fibrillation 18%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 17 147 $20,440

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $202
  • PFIZER INC. $25
$227 151 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $132
$132 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $97
$97 — —
Trelstar
  • Verity Pharmaceuticals Inc. $96
$96 — —
ERLEADA
  • Janssen Biotech, Inc. $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

431 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record